
With the Dividend Data connector, your AI app answers from the same data as this page and links the page behind each number. A free Dividend Data account connects.
Questions to try
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage, for any covered stock.
TapClick below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
TapClick below to see what's inside, then upgrade to unlock for AZN.L and 80,000+ other tickers.
See price against where its own fundamentals say it should trade. The shaded gap is the discount or premium, across five valuation lenses here and all seven in the Value Graph.
TapClick below to see what's inside, then upgrade to unlock for AZN.L and 80,000+ other tickers.
See exactly how AZN.L's revenue becomes profit: a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for AZN.L and 80,000+ other tickers.
AstraZeneca PLC operates as a biopharmaceutical company, specializing in the discovery, development, manufacturing, and commercialization of prescription medications. Its comprehensive portfolio addresses diverse therapeutic areas. In oncology, key marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex. For cardiovascular, renal, and metabolism diseases, the company offers treatments such as Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma…

AstraZeneca PLC (LON: AZN - Get Free Report) passed above its 200-day moving average during trading on Friday. The stock has a 200-day moving average of £134.30 and traded as high as £140.02. AstraZeneca shares last traded at £139.96, with a volume of 40,274,711 shares changing hands. Trending Headlines about AstraZeneca Here are the key news

AstraZeneca (LON: AZN - Get Free Report)'s stock had its "buy" rating reiterated by research analysts at Jefferies Financial Group in a report issued on Wednesday, Digital Look reports. They currently have a £175 price objective on the biopharmaceutical company's stock. Jefferies Financial Group's price target suggests a potential upside of 45.52% from the company's current

AstraZeneca PLC (LON: AZN - Get Free Report) insider Michel Demare bought 2,500 shares of AstraZeneca stock in a transaction dated Monday, September 14th. The stock was purchased at an average price of £121.21 per share, for a total transaction of £303,025. AstraZeneca Stock Down 0.3% AZN opened at £121.16 on Wednesday. The firm's 50-day simple

Citi has flagged AstraZeneca PLC's (LSE:AZN, NASDAQ:AZN) accelerated approval for Etcamah, known chemically as camizestrant, as a meaningful sentiment...

Anteris Technologies Pty Ltd (ASX:AVR, NASDAQ:AVR) has appointed experienced financial executive Brent Moen as chief financial officer, effective September...